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Brief Technique ReportsCompassionate aortic valve implantation for severe
aortic regurgitationGregory Ducrocq, MD, Dominique Himbert, MD, Ulrik Hvass, MD, and Alec Vahanian, MD, Paris, FranceWe report the case of a young woman with severe rheu-
matic aortic insufficiency who was treated by transcatheter
aortic valve implantation (TAVI) because of contraindica-
tion to conventional valve replacement. The questions raised
by this case are discussed.CLINICAL SUMMARY
A 36 year-old woman was admitted to our department for
worsening dyspnea (New York Heart Association class III)
caused by severe aortic regurgitation (AR). Her medical his-
tory included rheumatic heart disease and a breast cancerFIGURE 1. Severe aortic regurgitation (AR) as observed by means of preproce
analysis caused by rheumatic aortic valve disease. Postimplantation angiograph
position of the CoreValve System and trivial paraprosthetic leak. LV, Left ventr
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was recently complicated by sternal metastases.
On admission, the patient was in good general condition,
with a blood pressure of 100/50 mmHg, and clinical signs of
severe AR were present. Electrocardiographic analysis
showed left ventricular (LV) hypertrophy and incomplete
right bundle branch block. Transthoracic echocardiographic
analysis confirmed the severity of the AR: regurgitant orifice
area, 0.40 cm2; regurgitant volume, 75 mL (Figure 1, B); LV
dilatation; end-systolic diameter, 49 mm; and decreased
ejection fraction (45%). AR was of rheumatic cause, with
mild calcifications, and was associated with a mild mitral re-
gurgitation (regurgitant orifice area, 0.10 cm2; regurgitant
volume, 11 mL). The diameter of the aortic annulus was
24 mm. The ascending aorta was moderately dilated (40
mm). Systolic pulmonary artery pressure was 60 mm Hg.
Supra-aortic angiographic analysis showed a grade 3 AR
(Figure 1, A), and results of coronary angiographic analysis
were normal. A multidisciplinary discussion with oncolo-
gists and cardiac surgeons led to the conclusion that life ex-
pectancy was approximately 2 years and the surgical risk of
aortic valve replacement was exceedingly high because ofdure supra-aortic angiographic (A) and transthoracic echocardiographic (B)
ic (C) and transthoracic echocardiographic (D) analysis showed the good
icle; Ao, aorta; LA, left atrium.
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FIGURE 2. Invasive hemodynamic findings before (A) and after (B) CoreValve System implantation showing immediate decrease of left ventricular end-
diastolic pressure and increase in diastolic aortic pressure after implantation. C, Aortic pressure during rapid ventricular pacing used for CoreValve System
implantation.
Brief Technique Reportsmediastinal radiation and sternal metastases. Thus a compas-
sionate TAVI was considered. After informed consent was
obtained, a 29-mm Medtronic CoreValve System (Med-
tronic, Inc, Minneapolis, Minn) was implanted by means
of percutaneous femoral access. Contrary to the usual tech-
nique in patients with aortic stenosis, balloon predilatation
was not done, and rapid ventricular pacing was performed
to stabilize the prosthesis during its implantation and avoid
migration (Figure 2, C). In addition, continuous transeso-
phageal echocardiographic (TEE) guidance was most useful
for optimal positioning, which was rendered difficult by the
absence of valve calcification serving as a landmark. After
implantation, dilatation with a 25-mm-diameter balloon
was necessary to obtain an adequate deployment of the pros-
thesis. TEE and supra-aortic angiographic analysis showed
its good position and a trivial residual AR (Figure 1, C).
The mean gradient decreased from 25 mm Hg before im-
plantation to 8 mm Hg, and LV end-diastolic pressure de-
creased from 28 to 17 mm Hg (Figure 2, A and B).
Complete atrioventricular block occurred at day 3 and re-
quired permanent pacemaker implantation. In-hospital out-
come was otherwise uneventful. Predischarge transthoracic
echocardiographic analysis showed a circular shape of the
prosthesis, with no significant impairment of the mitral
valve, a trivial intraprosthetic AR and a grade 1/4 internal
paraprosthetic AR (Figure 1,D). The patient was discharged
at day 12 in New York Heart Association class I.The Journal of Thoracic and CaDISCUSSION
To date, the only admitted indication for TAVI is the treat-
ment of patients with severe symptomatic aortic stenosis and
high risk for, or contraindications to, aortic valve replace-
ment.1 This indication has given satisfactory survival and
functional results up to 3 years. However, preliminary re-
ports suggested feasibility and good short-term results
with ‘‘off-label’’ uses of TAVI, the first of which being
treatment of degenerated aortic bioprostheses.2-4
To our knowledge, this is the first report of TAVI to treat
severe AR in a native valve, and it raises 3 main questions.
The first relates to the clinical context that led to this deci-
sion. In addition to her cancer, this young and still very ac-
tive woman was severely and increasingly disabled by her
valve disease, and comprehensive multidisciplinary evalua-
tion precluded any surgical options. Although her life expec-
tancy was probably limited, it was estimated to be at least
around 2 years. Thus it was mandatory to find an alternative
to improve her quality of life.
The second question relates to the technical aspects of
prosthesis implantation. Hyperkinetic cardiac motion
caused by AR and absence of angiographic landmarks in-
creased the risks of misplacement and migration of the
prosthesis. This report shows that they could be effectively
managed by using careful fluoroscopic and TEE guidance
and rapid ventricular pacing. Finally, TAVI was techni-
cally feasible because the AR was of rheumatic and notrdiovascular Surgery c Volume 140, Number 4 931
Brief Technique Reportsdystrophic nature, with no severe dilatation of the aortic
root.
The third question relates to the risk of complete atrioven-
tricular block after CoreValve System implantation. Several
predictors, including pre-existing right bundle branch block,
have been determined and should lead to careful and pro-
longed predischarge monitoring, all the more because these
conduction disturbances can be delayed, as was the case in
the present report.5
In the future, the treatment of AR by means of TAVI will
probably remain restricted to very particular and individual
cases but might be life-saving or contribute to an improve-
ment in the functional status of patients with no other
therapeutic options.From the Divisions of Cardiothoracic Surgerya and Cardiology,b Columbia University
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difficult resternotomyHiroo Takayama, MD,a Yoshifumi Naka, MD, PhD,a Ulrich P. Jorde, MD,b and Allan S. Stewart, MD,a
New York, NYLeft ventricular assist devices (LVADs) are playing an in-
creasingly important role in the management of end-stage
heart failure, especially with the advances in technology in
implantable LVADs. Placement of an implantable LVAD
generally requires a median sternotomy, and this approach
might not be suitable for unstable patients with difficult
resternotomy. Even in such a situation, however, current
state-of-the-art technology can provide mechanical circula-
tory support either with extracorporeal membrane oxygena-
tion (ECMO) or, more recently, with percutaneous
LVADs.1,2 The shortcoming of the latter modalities is that
they are not designed for prolonged periods of support.
Here we describe a unique configuration of the CentriMag
LVAD (Thoratec Corp, Pleasanton, Calif) that allowed rapid
off-pump placement of the device without performing a ster-
notomy.CLINICAL SUMMARY
The patient was a 50-year-old man (height, 180 cm;
weight, 105 kg) with nonischemic dilated cardiomyopathy.
He previously had 2 sternotomies; the first was an aortic
valve replacement with a mechanical valve for congenital
bicuspid aortic valve 8 years ago, and the second was a hem-
iarch repair of a type A aortic dissection 4 years ago. The
patient first had symptoms of congestive heart failure
(CHF) about 6 years ago, with recent progression requiring
multiple hospitalizations, and was listed for heart transplan-
tation. His condition recently further deteriorated, with
acutely decompensated CHF and ventricular arrhythmia re-
quiring admission to the intensive care unit. Although CHF
improved with infusion of inotropic agents, ventricular
arrhythmia persisted and became more frequent, with
multiple firings of his implantable cardioverter defibrillator.
Intra-aortic balloon pump therapy was not applicable
because of the remaining aortic dissection in the descending
aorta. At this point, urgent LVAD support was deemed
necessary.
The patient was taken to the operating room. In the supine
position general anesthesia was induced with a single-lumen
endotracheal tube. The previous right axillary artery cannu-
lation site was opened, and the artery was exposed. A left an-
terior minithoracotomy through the sixth intercostal space
was performed, and the left ventricular apex was exposed
by dissecting some loose adhesion inside of the pericardium.ery c October 2010
